科研之友
微信
新浪微博
Facebook
分享链接
摘要
Background: Beckman Coulter recently released a new cardiac troponin I (cTnI) assay, AccuTnI+3, for the Access 2 and DxI platforms. We validated the stated 99th percentile (20 ng/l) using a large population of healthy adults representative of the Northern California population. Methods: Within a large sample of healthy adult members receiving care at Kaiser Permanente, cTnI was quantified in residual specimens using the AccuTnI+3 assay. Patients were selected based on pre-defined criteria extracted from a comprehensive electronic medical record. All specimens with a cTnI concentration >30 ng/l were repeated; specimens that had a reproducible result >30 ng/l were subject to heterophile blocking procedure. 99th percentiles were calculated based on age, sex, race and body mass index categories. Results: Among 1764 tested subjects, the 99th percentile for all samples was 25 ng/l. Sex differences were observed; the male and female 99th percentiles were 31 and 21 ng/l, respectively (p = 0.001). Age (range evaluated 18-89 y, median 47 y) also had a significant influence on the value (p = 0.003), but there were no significant differences by race. False positive results were detected in 0.9% of specimens (0.6% "fliers" and 03% heterophile antibodies), corresponding to 52% of all results >30 ng/l. Conclusions: Among a large, representative cohort of healthy adults, we found a 99th percentile value consistent with prior studies based on highly selected small patient samples. Sex and age-specific upper reference limits for cTnI should be considered. In this cohort, about half the findings above the 99th percentile were false positives. Avoiding reporting erroneous results requires implementation of quality indicators.
